No one would argue that MSB hasn’t spent a lot of capital, that isn’t the point and doesn’t really answer my question. I am interested in whether they are at a stalemate while trying to resolve the potency issues or whether trials are allowed to move forward in tandem. Obviously the timeline is a concern given the cash balance.
disclosure - I held MSB a few years ago (before COVID) and sold for a healthy profit, holding through phase 3 trial results didn’t suit my risk appetite.
replying to @Sector above
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-53
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.06 |
Change
0.030(2.91%) |
Mkt cap ! $1.230B | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.09 | $1.03 | $3.968M | 3.719M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 26178 | $1.06 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 11784 | 9 |
View Market Depth
| Last trade - 12.42pm 02/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |